Published in Vaccine Weekly, October 19th, 2005
According to the company, the move is designed to ensure children do not go unvaccinated after the recommendation from the European Medicines Agency (EMEA) to suspend the marketing authorization for Hexavac vaccine (DTPa, hep B, IPV, Hib) from Sanofi Pasteur, MSD, as a precautionary measure.
GSK's Infanrix hexa differs significantly from Hexavac and is not impacted by this...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.